Lonza's potential Catalent buy remains under wraps

Lonza HQ

Scant information has emerged since reports began to circulate late last week that Swiss life sciences company Lonza Group ($LONN) was making a run at Catalent ($CTLT), a U.S.-based drug delevoper.

In a report that cited unnamed sources, Reuters said the two were in talks. The news sent Catalent shares soaring 12%, boosting its market capitalization to almost $4 billion.

Those same sources, however, said the two sides had been, so far, unable to agree on a price for Catalent. Lonza has been in an acquisition mode in recent years, snapping up smaller bioscience companies in the U.S. Back in 2011, Lonza shelled out $1.4 billion for chemical maker Arch Chemicals.

Both companies declined to comment on the rumors.

If Lonza, which has a market capitalization of about $9 billion, were to reach terms for Catalent it would give the Swiss company a bigger reach in the life sciences arena and the capability to produce an expanded line of molecules for active pharmaceutical ingredients and drug delivery, the news agency said.

New Jersey-based Catalent, which has 31 facilities globally, has only been publicly traded since 2014. It was acquired from Cardinal Health ($CAH) by private equity firm Blackstone Group ($BX) in 2007 for $3.3 billion.

- here’s the Reuters story

Read more on

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.